Global Biomarkers Standardization Consortium  
March 18, 2020  
10 a.m. Central / 11 a.m. Eastern / 3 p.m. GMT / 4 p.m. CET

Meeting Summary

Attendees (Names taken from webinar attendee information if a name was listed. This is not a complete list of attendees. There were ~85 attendees): Rebecca Edelmayer, Chris Weber, Jeffrey Dage, Alexander Jethwa, Andrea Tenner, Britta Brix, Melissa Budelier, Blaine Roberts, Chad Logan, Charlotte Teunissen, Eline Willems, Emily Meyers, Emily Turner, Erik Stoops, Eugeen Vanmechelen; Gina Jerome, Hanno Steen, Henrik Zetterberg, Ian Sherrick, Inge Verberk, Jim Boslett, Johan Gobom, Johan Lindborg, John Lawson, Julia Gray, Kaj Blennow, Kelley Coalier, Kelley Faber, Kevin Yarasheski, Kim Green, Kira Sheinerman, Koen Dewaele, Kristina Malzbender, Kwasi Mawuenyega, Laura Nisenbaum, Leslie Shaw, Leticia Sarasa, Leyla Anderson, Lynn Bekris, Manu Vandijck, Mark Lowenthal, Matt Fagerburg, Michelle Mielke, Mike Edler, Nathalie Le Bastard, Nathan Yates, Nicholas Ashton, Nina Silverberg, Paige Lacatena, Pedro Pensini, Rachel Henson, Randy Slemmon, Rianne Esquivel, Richard Dennis, Robert Rissman, Robert Dean, Rosa Canet-Aviles, Stefania Forner, Sudhir Sivakumar, Sunil Pandit, Sylvain Lehmann, Tarick Ali Pascoal, Thomas Karikari, Tom McAvoy, William Chen, April Ross, Jose Luis Molinuevo, Noelia Fandos, Robert Martone, Adam Simon, Tobias Bittner, Moucon Yuan, Chiaki Yoda, Klaus Romero.

- Welcome and Roll Call (Chris Weber)
  - The Alzheimer’s Association International Conference (AAIC) 2020 is moving forward as planned, July 24-30.

  The Alzheimer’s Association is closely monitoring developments related to COVID-19. The health and safety of our attendees, volunteers, staff and all of our constituents are our top priority.

  The Alzheimer’s Association is tracking all health and travel restrictions issued by governments globally, as well as guidance from the World Health Organization (WHO), the Netherlands National Institute for Public Health and others. Additional updates will be provided at www.alz.org/aaic and via email for registrants. For specific inquiries, please contact aaic@alz.org.

- The GBSC F2F meeting will occur on Friday July 25, 2020. Registration and agenda will be provided later in the spring and any ideas for agenda items can be emails to Dr. Chris Weber directly at cweber@alz.org.

- Plasma p-tau as a biomarker for Alzheimer’s disease (Jeff Dage)
  - Recently two papers have been published in Nature medicine covering phospho-Tau 181 in plasma and the potential use as a diagnostic tool.
Results from the BioFINDER study indicate that p-Tau 181 in blood was fairly specific for AD dementia, when compared to non-AD dementia. p-Tau 181 in blood was closely correlated to Tau PET data and p-Tau in blood was indicative of tau PET positivity. Similar results observed in autopsy samples. Results were similar to those observed in a UCSF study. p-Tau 181 in blood was also a good indicator of Aβ positivity. p-Tau 181 was able to predict patients that would go on to develop AD (AD converters).

Collaborations with Fujirebio and Kaj Blennow and Henrik Zetterberg using multiple platforms and different cohorts show assays correlate with similar results across platforms.

Further optimization and study is needed, but plasma pTau has promising clinical utility.

Update on the biorepository on mistreated samples for development on preanalytical protocol for blood (Inge Verberk)

The focus of this study is to gain a consensus on preanalytical effects on blood biomarkers to develop a uniform blood handling SOP that will apply to all platforms. Preanalytical phases covers everything from the sample collection to storage, including collection tube type, standing time between collection and centrifugation, temperature of standing time, centrifugation temperature, aliquot size, storage temperature and freeze/thaw cycles.

Blood samples from 90 individuals have been collected at Amsterdam UMC Hospital. Blood was mistreated according to study design with 10 sample sets per protocol, 6 aliquots each. One aliquot for Amsterdam UMC and the others for external lab analysis.

Early results indicate that amyloid levels are impacted by collection tube type, when samples are standing for 24hr at RT (not when kept at 4°C), and when stored at 4°C for 2 weeks. Overall NfL and GFAP were stable with additional analysis needed.

Next steps are to send samples to other labs for analysis in a wide variety of markers and platforms.

Update on reference material commutability and harmonization of methods using the CRM (Britta Brix)

Previously, Euroimmun, Fujirebio and Roche formed a group to test and calibrate Aβ42 CRM on Aβ1-42 assays. Results led to all companies recalibrating assays.

Next Euroimmun and Fujirebio aim to compare neat CSF samples in re-calibrate tests using 25 frozen samples with some variable results (possibly due to sample handling, materials, assays). Last year companies decided to continue to work together to identify second study to compare neat CSF samples in side by side study.

In the Commercial Ring trial (INSTAND) samples are analyzed twice a year to measure amyloid, tau, p-tau 181. Results from October 2019 show alignment
between calibrated Fujirebio and Euroimmun groups, and will continue to next round.

- In the future, all companies must do more validation studies and samples are needed, though difficult to obtain. How can we (academia and companies) work together to create a pool of samples for validation purposes? Alzheimer’s Association can take lead on forming a workgroup through GBSC to address this need. Company representatives can regroup to determine what exactly is needed in terms of sample type.